Drug Trials 'Snapshots' Could Get Photoshopped, CDER Says
Executive Summary
Sponsors who disagree with how racial, gender and age-related demographic subgroup data for their products are described in public summaries may propose revisions and submit them for FDA consideration.
You may also be interested in...
US FDA's New Website May Facilitate Broader Outside Use Of Data
Redesigned FDA.gov is expected to allow application programming interfaces, which could allow other software to talk to the site and potentially use its data.
FDA Commissioner Candidate Gulfo Hates Breakthrough, Wants To Reevaluate User Fees
In an interview, Joseph Gulfo, former medtech industry CEO and vocal FDA critic, outlines his worldview and interest in pushing aggressively against increasing the FDA ‘body of law.’
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.